Evidence map›Paper›PMID 37606480›Full record

ArticleInternational journal of neonatal screening2023

Shadow of a Pandemic: Persistence of Prenatal SARS-CoV-2 Antibodies in Newborn Blood Spots.

Stanley Sciortino, Steve Graham, Toki Fillman, Hari Kandasamy, Robin Cooley, Carl Hanson, Valorie Eckert, Hao Tang, Juan Yang, David Seftel and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of neonatal screening, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Stanley SciortinoGenetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA.ORCID 0000-0002-6191-8179
Steve GrahamGenetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA.
Toki FillmanGenetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA.
Hari KandasamyGenetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA.
Robin CooleyGenetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA.
Carl HansonViral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA 94804, USA.ORCID 0000-0001-9569-2932
Valorie EckertGenetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA.
Hao TangGenetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA.
Juan YangGenetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA.
David SeftelEnable Biosciences, South San Francisco, CA 94080, USA.
Cheng-Ting TsaiEnable Biosciences, South San Francisco, CA 94080, USA.
Peter RobinsonEnable Biosciences, South San Francisco, CA 94080, USA.
California Department of Public Health · USEnable Biosciences (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate COVID-19 surveillance among pregnant women, the California Genetic Disease Screening Program conducted a screening performance and seroprevalence evaluation of maternal SARS-CoV-2 antibodies detected in banked newborn dried blood spots (DBS). We obtained seropositive results for 2890 newborn DBS from cohorts in 2020 and 2021 using Enable Bioscience's Antibody Detection by Agglutination-PCR (ADAP) assay for SARS-CoV-2 antibodies. To infer maternal infection, we linked 312 women with a known laboratory-confirmed COVID-19 episode with their newborn's DBS SARS-CoV02 antibody result. Among 2890 newborns, we detected 453 (15.7%) with SARS-CoV-2 antibodies in their DBS. Monthly snapshot statewide seroprevalence among neonates was 12.2% (95% CI 10.3-14.1%,

Indexed as

antibody testingCOVID-19dried blood spotsnewbornnewborn screeningpositive predictive valuepregnancyprenatalSARS-CoV-2seroprevalenceserosurveillance

Identifiers

PMID37606480
PMCPMC10443380
OpenAlexW4385481002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.